Category icon
Management of Chronic Coronary Disease and Acute Coronary Syndromes in…

Karthiek R Narala, Thomas A LaLonde, Sohail Hassan, et al

Category icon
ACC 2021 Discussion: The ISCHEMIA Trial

Gregg Stone, Harriette Van Spall

Category icon
Antithrombotic Therapy in Complex PCI Patients Under OAC

Despoina-Rafailia Benetou, Panayotis K Vlachakis, Charalampos Varlamos, et al

Category icon
Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin

Johny Nicolas, Usman Baber, Roxana Mehran,

Category icon
ACC 2018: TREAT Late Breaking Trial

Otavio Berwanger, Prof José C Nicolau

Category icon
USC 21 Discussion: Optimal Antiplatelet Regimen in HBR

Mirvat Alasnag, Khaled Al-Shaibi, Roisin Colleran et al

Category icon
Antithrombotics in TAVR

Mathew R Williams, Kelsey Grossman, Homam Ibrahim,

Category icon
Clopidogrel Resistance?

Michael D Almaleh, Scott Moore, Charles L Campbell,

Category icon
ACC 2018: TREAT Late Breaking Trial

Prof José C Nicolau, Christopher B Granger

About

Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the current gold standard for the treatment of acute coronary syndrome (ACS). Clopidogrel or ticagrelor are the preferred P2Y12 inhibitor options for initial therapy. Ticagrelor has been demonstrated to have improved efficacy, and is preferred over clopidogrel in the absence of contraindications or the need for oral anticoagulation.

The main risk associated with all antiplatelet therapies is bleeding, and physicians need to carefully weigh the possible adverse effects against the benefits of prescribing these drugs to patients with ACS. Aspirin continues to be prescribed almost ubiquitously for patients with ACS, and P2Y12 antagonists are now often added in; such dual antiplatelet therapy confers greater antithrombotic efficacy but at the risk of increased bleeding. Over recent years, it has become apparent that these drugs may also exert powerful anti-inflammatory effects that provide additional benefit in the management of ACS.

Related Articles

Articles

Antithrombotic Therapy in Complex PCI Patients Under OAC

Despoina-Rafailia Benetou, Panayotis K Vlachakis, Charalampos Varlamos,

Published:

Citation: US Cardiology Review 2021;15:e09.

Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin

Johny Nicolas, Usman Baber, Roxana Mehran,

Published:

Citation: US Cardiology Review 2020;14:e04.

Antithrombotics in TAVR

Mathew R Williams, Kelsey Grossman, Homam Ibrahim,

Published:

Citation: US Cardiology Review 2019;13(2):88–93.

Optimizing Crossover From Ticagrelor to Clopidogrel

Donald E Cutlip,

Citation: US Cardiology Review 2017;11(2):59–61.